Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 80.39 USD 0.26%
Market Cap: 31.4B USD
Have any thoughts about
Dexcom Inc?
Write Note

Dexcom Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dexcom Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Dexcom Inc
NASDAQ:DXCM
Accounts Payable
$326.6m
CAGR 3-Years
16%
CAGR 5-Years
26%
CAGR 10-Years
45%
Becton Dickinson and Co
NYSE:BDX
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accounts Payable
$907m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
15%
Stryker Corp
NYSE:SYK
Accounts Payable
$1.3B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
15%
Abbott Laboratories
NYSE:ABT
Accounts Payable
$4B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
15%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Payable
$218.7m
CAGR 3-Years
22%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

Dexcom Inc
Glance View

Market Cap
31.4B USD
Industry
Health Care
Economic Moat
Narrow

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
44.01 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Dexcom Inc's Accounts Payable?
Accounts Payable
326.6m USD

Based on the financial report for Sep 30, 2024, Dexcom Inc's Accounts Payable amounts to 326.6m USD.

What is Dexcom Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
45%

Over the last year, the Accounts Payable growth was 35%. The average annual Accounts Payable growth rates for Dexcom Inc have been 16% over the past three years , 26% over the past five years , and 45% over the past ten years .

Back to Top